AKT1 and cancer: These findings were confirmed at the protein level in in vitro and in vivo, and were consistent with our microarray data analysis (see Text S1, Fig. S1, Tables S1, S2, S3), that FBA-TPQ exerts its activity mainly through its induction of ROS and DNA damage, regulation of the ‘pathway in cancer’, ‘p53 signaling pathway’ and ‘phosphatidylinositol signaling system’ (e.g., PI3K-Akt), as well as its negatively regulation of CDK (e.g., CDK1 and the related CDC25C and CyclinB1).